JP2005511005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511005A5 JP2005511005A5 JP2003514012A JP2003514012A JP2005511005A5 JP 2005511005 A5 JP2005511005 A5 JP 2005511005A5 JP 2003514012 A JP2003514012 A JP 2003514012A JP 2003514012 A JP2003514012 A JP 2003514012A JP 2005511005 A5 JP2005511005 A5 JP 2005511005A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- collagen
- gpvi
- protein according
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 32
- 102000037865 fusion proteins Human genes 0.000 claims 32
- 229920001436 collagen Polymers 0.000 claims 17
- 235000018102 proteins Nutrition 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000008186 Collagen Human genes 0.000 claims 8
- 108010035532 Collagen Proteins 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- 102100038394 Platelet glycoprotein VI Human genes 0.000 claims 2
- 101710194982 Platelet glycoprotein VI Proteins 0.000 claims 2
- 108010023197 Streptokinase Proteins 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 229960002897 heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 108010011655 saratin Proteins 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 229960005202 streptokinase Drugs 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 230000010807 negative regulation of binding Effects 0.000 claims 1
- 230000010118 platelet activation Effects 0.000 claims 1
- 230000012354 positive regulation of binding Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01116717 | 2001-07-18 | ||
| PCT/EP2002/007796 WO2003008454A2 (en) | 2001-07-18 | 2002-07-12 | Glycoprotein vi fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005511005A JP2005511005A (ja) | 2005-04-28 |
| JP2005511005A5 true JP2005511005A5 (enExample) | 2006-01-05 |
Family
ID=8177994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003514012A Pending JP2005511005A (ja) | 2001-07-18 | 2002-07-12 | 糖タンパク質ｖｉ融合タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7507412B2 (enExample) |
| EP (1) | EP1406929A2 (enExample) |
| JP (1) | JP2005511005A (enExample) |
| AU (1) | AU2002333241B2 (enExample) |
| CA (1) | CA2453986A1 (enExample) |
| WO (1) | WO2003008454A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011274A (es) | 1999-05-07 | 2002-05-06 | Merck Patent Gmbh | Glicoproteina vi recombinante del receptor de colageno sobre plaquetas y su uso farmaceutico. |
| US20070071744A1 (en) * | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
| US20090130021A1 (en) * | 2002-06-07 | 2009-05-21 | Gotz Munch | Methods, products and uses involving platelets and/or the vasculature |
| US7531178B2 (en) * | 2002-06-07 | 2009-05-12 | Trigen Gmbh | Immunoadhesin comprising a glycoprotein VI domain |
| EP1369128A1 (en) * | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
| EP1824979A2 (en) * | 2004-12-10 | 2007-08-29 | Trigen GmbH | Methods, products and uses involving platelets and/or the vasculature |
| EP1876240B1 (en) * | 2005-04-28 | 2012-08-22 | Mochida Pharmaceutical Co., Ltd. | Anti-human platelet membrane glycoprotein vi monoclonal antibody |
| US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| SI1873166T1 (sl) | 2006-06-30 | 2011-01-31 | Conaris Res Inst Ag | IZBOLJĹ ANI sgp 130Fc DIMERJI |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| EP1916259A1 (en) | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
| US8278271B2 (en) * | 2006-12-13 | 2012-10-02 | University Of Massachusetts | Inhibiting collagen-induced platelet aggregation and activation with peptide variants |
| US10113156B2 (en) | 2009-03-04 | 2018-10-30 | Board Of Regents, The University Of Texas System | Stabilized reverse transcriptase fusion proteins |
| US9150897B2 (en) * | 2010-08-06 | 2015-10-06 | The Regents Of The University Of California | Expression and purification of fusion protein with multiple MBP tags |
| AU2012364736A1 (en) | 2011-12-19 | 2014-07-24 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| HK1218553A1 (zh) | 2013-02-01 | 2017-02-24 | Santa Maria Biotherapeutics, Inc. | 抗激活素a化合物对受试者的施用 |
| US20140220033A1 (en) * | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| PL3226888T3 (pl) | 2014-12-01 | 2021-11-02 | Ferring B.V. | Podawanie selektywnego transsygnałowego inhibitora IL-6 |
| DK3227325T3 (da) | 2014-12-01 | 2024-07-08 | Ferring Bv | Sammensætninger med selektive hæmmere af il-6-trans-signalering |
| MX2018001465A (es) | 2015-08-05 | 2019-01-31 | Acticor Biotech | Nuevos anticuerpos anti-gpvi humana y sus usos. |
| SG11201906530TA (en) | 2017-02-03 | 2019-08-27 | Acticor Biotech | Inhibition of platelet aggregation using anti-human gpvi antibodies |
| CN109836501A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向her2的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109837304A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向her2的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109837246A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向ror1的嵌合抗原受体t细胞及其制备方法和应用 |
| EP4182338A1 (en) * | 2020-07-17 | 2023-05-24 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| CN111875697B (zh) * | 2020-08-03 | 2021-10-01 | 杭州皓阳生物技术有限公司 | 一种包含肽标签的融合蛋白 |
| EP4355340A4 (en) * | 2021-06-16 | 2025-05-21 | Instil Bio, Inc. | RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773574A (en) * | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
| US5525491A (en) * | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| ATE267215T1 (de) * | 1997-12-08 | 2004-06-15 | Lexigen Pharm Corp | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung |
| CA2367457C (en) * | 1999-03-18 | 2010-09-21 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Protein for blocking platelet adhesion |
| MXPA01011274A (es) * | 1999-05-07 | 2002-05-06 | Merck Patent Gmbh | Glicoproteina vi recombinante del receptor de colageno sobre plaquetas y su uso farmaceutico. |
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US6245527B1 (en) * | 1999-06-30 | 2001-06-12 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof |
| US20030144187A1 (en) * | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
| DE10018860A1 (de) * | 2000-04-14 | 2001-10-18 | Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh | Stabilisierung des Betriebs von Gasentladungslampen |
-
2002
- 2002-07-12 EP EP02787127A patent/EP1406929A2/en not_active Withdrawn
- 2002-07-12 AU AU2002333241A patent/AU2002333241B2/en not_active Ceased
- 2002-07-12 WO PCT/EP2002/007796 patent/WO2003008454A2/en not_active Ceased
- 2002-07-12 JP JP2003514012A patent/JP2005511005A/ja active Pending
- 2002-07-12 CA CA002453986A patent/CA2453986A1/en not_active Abandoned
- 2002-07-12 US US10/483,810 patent/US7507412B2/en not_active Expired - Fee Related
-
2007
- 2007-11-27 US US11/987,079 patent/US20080206247A1/en not_active Abandoned
-
2008
- 2008-10-02 US US12/244,339 patent/US20090155897A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511005A5 (enExample) | ||
| Jones et al. | Fibronectin glycosylation modulates fibroblast adhesion and spreading. | |
| CN100525829C (zh) | 检测混合物中配体和靶标的方法 | |
| US7507412B2 (en) | Glycoprotein VI fusion proteins | |
| KR100210183B1 (ko) | 세포-유리된 수용체 결합 검정물, 이의 제조방법 및 용도 | |
| Lentz et al. | Synthetic peptides corresponding to sequences of snake venom neurotoxins and rabies virus glycoprotein bind to the nicotinic acetylcholine receptor | |
| US10358464B2 (en) | Specific binding sites in collagen for integrins and use thereof | |
| Behera et al. | Borrelia burgdorferi BBB07 interaction with integrin α3β1 stimulates production of pro‐inflammatory mediators in primary human chondrocytes | |
| Xie et al. | Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv | |
| AU2002333241A1 (en) | Glycoprotein VI fusion proteins | |
| JPH029391A (ja) | 大食細胞誘導炎症性神経細胞 | |
| Liang et al. | Identification of novel heparin-binding domains of vitronectin | |
| WO2002022820A1 (en) | Inhibition of stenosis or restenosis by p-selectin antagonists | |
| Tandon et al. | Interaction of human platelets with laminin and identification of the 67 kDa laminin receptor on platelets | |
| Mathelié-Guinlet et al. | Single-molecule analysis demonstrates stress-enhanced binding between Staphylococcus aureus surface protein IsdB and host cell integrins | |
| Furthmayr | Immunochemistry of the extracellular matrix | |
| Bayrak et al. | Novel small-molecule atypical chemokine receptor 3 agonists: design, synthesis, and pharmacological evaluation for antiplatelet therapy | |
| US7772368B2 (en) | Deletion forms of IGE-dependent histamine releasing factor having histamine releasing activity, HRF-binding peptides and the uses thereof | |
| ES2293635T3 (es) | Metodo para reducir la inmunogenicidad de la region variable de anticuerpos. | |
| Hildebrand et al. | Characterization and identification of heparin-induced nonopioid-binding sites for beta-endorphin in human plasma. | |
| Amblard et al. | Synthesis and biological evaluation of bradykinin B1/B2 and selective B1 receptor antagonists | |
| JP2002523041A (ja) | 第２の機能的ドメインを有するストレプトアビジン変異体 | |
| EP2919013B1 (de) | Verfahren zur Detektion von Modulatoren der GPIb-Thrombin-Interaktion | |
| JP2003514548A5 (enExample) | ||
| WO2013025598A1 (en) | Degranulation indicator and methods of use thereof |